Merck to Acquire Bio-Techne in Cash Deal
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Bio-Techne ( (TECH) ) has issued an announcement.
On June 25, 2026, Merck KGaA, Darmstadt, Germany and Bio-Techne Corporation announced a definitive agreement under which Merck will acquire Bio-Techne for $73 per share in cash, implying an enterprise value of about $11.3 billion and a 36% premium to Bio-Techne’s recent trading average. The transaction is expected to be immediately accretive to Merck’s sales growth and EBITDA margin after closing, with projected annual cost synergies of roughly €140 million by year three.
The combination would unite two highly complementary life science businesses, broadening Merck’s portfolio across multi-omics, spatial biology, precision diagnostics, and cell and gene therapy, while enhancing its Process Solutions unit with higher-value reagents, analytics and workflow technologies. Bio-Techne, which generated over $1.2 billion in fiscal 2025 sales and employs more than 3,000 people across 34 sites, would gain access to Merck’s global scale, manufacturing infrastructure and omnichannel reach, positioning the combined group to better serve complex next-generation biology workflows and deliver increased value to shareholders and customers, pending regulatory and shareholder approvals.
The most recent analyst rating on (TECH) stock is a Buy
with a $65.00 price target.
To see the full list of analyst forecasts on Bio-Techne stock,
see the TECH Stock Forecast page.
Spark’s Take on TECH Stock
According to Spark, TipRanks’ AI Analyst, TECH is a Neutral.
TECH scores best on financial resilience (strong cash generation and low leverage), which helps offset weaker near-term fundamentals (margin compression and a sharp TTM revenue decline). The overall score is held back by bearish technicals (price below key moving averages with negative momentum) and a demanding valuation (high P/E with a low dividend yield). Earnings-call guidance was cautiously supportive on margin and a potential FY-2027 growth inflection, but near-term growth remains limited.
To see Spark’s full report on TECH stock,
click here.
More about Bio-Techne
Bio-Techne Corporation is a Minneapolis-based global provider of life science tools, analytical technologies and consumables, with core strengths in recombinant proteins, cytokines, growth factors, antibodies, immunoassay kits and advanced instruments such as ProteinSimple automated protein analysis systems. The company also offers spatial biology and diagnostic technologies like RNAscope, and supplies materials, analytics and process technologies for cell and gene therapy developers, generating more than $1.2 billion in net sales in fiscal 2025 across 34 locations and 15 manufacturing sites worldwide.
On June 25, 2026, Merck KGaA, Darmstadt, Germany agreed to acquire Bio-Techne for $73 per share in cash, valuing the U.S. life sciences tools maker at about $11.3 billion, a 36% premium to its one-month volume-weighted average price. The planned deal, executed via a definitive merger agreement, is expected to immediately boost Merck’s sales growth and EBITDA margin post-closing, deliver roughly €140 million in annual cost synergies by year three, and significantly expand Merck’s capabilities and reach in high-growth areas such as multi-omics, spatial biology, precision diagnostics and cell and gene therapy, while giving Bio-Techne greater global scale and channel access, subject to customary approvals and shareholder consent.
Average Trading Volume: 2,732,280
Technical Sentiment Signal: Hold
Current Market Cap: $8.81B
Find detailed analytics on TECH stock on TipRanks’ Stock Analysis page.
